- Home
- NCL vs HKPD Comparison
NCL vs HKPD Comparison
Compare NCL & HKPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NCL | HKPD |
|---|---|---|
| Founded | 2013 | 2016 |
| Country | United States | Hong Kong |
| Employees | N/A | 27 |
| Industry | | Other Pharmaceuticals |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5M | 6.9M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | NCL | HKPD |
|---|---|---|
| Price | $0.17 | $0.43 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 411.8K | 408.9K |
| Earning Date | 04-13-2026 | 08-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 51.43 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $15,349,854.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 9.86 | N/A |
| 52 Week Low | $0.10 | $0.32 |
| 52 Week High | $1.05 | $2.58 |
Technical Indicators
Market Signals| Indicator | NCL | HKPD |
|---|---|---|
| Relative Strength Index (RSI) | 53.08 | 38.04 |
| Support Level | $0.14 | $0.37 |
| Resistance Level | $0.17 | $0.71 |
| Average True Range (ATR) | 0.02 | 0.06 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 71.43 | 42.66 |
Price Performance
Historical ComparisonAbout NCL Northann Corp.
Northann Corp specialized in 3D-printed flooring solutions under its flagship brand, Benchwick. The company's operations span the full spectrum of additive manufacturing, from sourcing recycled ocean plastics to the final production of intricate flooring designs. It offers an extensive range of proprietary solutions, including Infinite Glass, DSE, TruBevel, and MattMaster, mainly through its sales network in North America and Europe.
About HKPD Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares
Cellyan Biotechnology Co Ltd formerly, Hong Kong Pharma Digital Technology Holdings Ltd operates in two main categories: OTC pharmaceutical cross-border e-commerce supply chain services, conducted through its Hong Kong subsidiary, Joint Cross Border, which it refers to as the Supply Chain Services division, and OTC pharmaceutical cross-border procurement and distribution, conducted through its Hong Kong subsidiary, V-Alliance, which it referred to as the Procurement and Distribution division. Based in Hong Kong, Joint Cross Border has established itself as a provider of third-party supply chain services in Mainland China's OTC pharmaceutical cross-border e-commerce market.